Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ritonavir · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Lopinavir/ritonavir | DRUG | - |
| Ritonavir | DRUG | - |
Inclusion: * HIV positive * Are at least 18 years old * Subject has not been treated for an active AIDS-defining opportunistic infection within 15 days of screening * HIV RNA level \> 1000 copies/mL * Previous therapy with at least one protease inhibitor, at least one non-nucleoside reverse transcr...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Ritonavir is used to treat HIV infections and has also been studied in HIV-related Kaposi's sarcoma. It is a small molecule antiviral developed by Abbott Laboratories. In HIV therapy it is commonly used as a pharmacokinetic booster alongside other protease inhibitors rather than as a standalone treatment.
Ritonavir targets the cytochrome P450 3A enzymes CYP3A4, CYP3A5, CYP3A43, and CYP3A7, acting as an inhibitor. By inhibiting these enzymes it slows the metabolism of co-administered protease inhibitors, raising their blood levels. This boosting effect is the basis for its role in combination HIV regimens.
Ritonavir is developed and manufactured by Abbott Laboratories, which trades under the ticker ABT. Abbott is the sponsor behind the clinical development program for the drug, including the Phase 3 study of ABT-378/ritonavir in HIV-infected patients.
Ritonavir has been studied in Phase 3 clinical development, with a Phase 3 trial in HIV-infected patients and a Phase 2 trial in HIV-related Kaposi's sarcoma. Both studies are listed as completed, and no trials are currently active in this dataset.
Two completed trials are registered for ritonavir. NCT00038636 was a Phase 3 randomized study of two doses of ABT-378/ritonavir in HIV-infected patients previously treated with protease inhibitors and non-nucleoside reverse transcriptase inhibitors, enrolling 36 patients across the United States, France, and Spain. NCT00002366 was a Phase 2 study of ritonavir in HIV-related Kaposi's sarcoma in Australia.
Ritonavir is an established HIV treatment that has been used in clinical practice, and its development program includes completed Phase 3 and Phase 2 trials. The trials registered here are listed as completed, with the Phase 3 study evaluating ABT-378/ritonavir in previously treated HIV-infected patients.